Inhibitory effect of 17aα-D-homo-ethynylestradiol-3-acetae combined with irradiation on melanoma B16 growth
SONG Na-ling, MENG Ai-min, WANG Yue-ying, WU Hong-ying, HE Xin, LI De-guan, WANG Xiao-chun, ZHANG Heng, LU Lu
Published 2012-05-25
Cite as Chin J Radiol Med Prot, 2012,32(03): 233-235. DOI: 10.3760/cma.j.issn.0254-5098.2012.03.003
Abstract
Objective To investigate the antitumor effect of 17aα-D-homo-ethynylestradiol-3-acetae on the mice transplanted with melanoma (B16) tumor cells,and to explore the possible synergistic effect with irradiation.Methods IRM-2 mice transplanted with B16 cells were randomly classified into control group,irradiation group,17aα-D-homo-ethynylestradiol-3-acetae drug ( high dose,medium dose,low dose) groups,and drug and irradiation combination group.Mice in drug group and the combination group were intraperitoneally injected with 5,7.5,and 10 mg/kg drug for 7 days.Mice in the irradiation and combination group received 1 Gy total body irradiation at 4 d after drug injection and then once a day for 5 days.The tumor inhibition efficiency,the number of bone marrow cells,thymus indices,and spleen indices were evaluated.Results Tumor weights in each drug group were significantly lower than those of the control( t =4.58,9.07,6.67,P < 0.05 ).Drug combinated with 137Csγ-rays enhanced the antitumor effect so that the tumor weights in the combination group were significantly decreased ( t =8.06,10.35,6.71,P <0.05 ) in comparison with the control groups.Moreover,the numbers of marrow nucleated cells,thymus index and spleen index in the drug group were higher than those in the control group ( t =2.64,3.80,2.84,P < 0.05 ).Conclusions 17aα-D-homo-ethynylestrudiol-3-acetae can inhibit cell growth of B16 melanoma in mice and may also have radioprotective effect on the hematopoietic system and immune system of mice.
Key words:
17aα-D-homo-ethynylestradiol-3-acetae; B16 melanoma; Radiation therapy; Tumor inhibition efficiency
Contributor Information
SONG Na-ling
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
MENG Ai-min
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
WANG Yue-ying
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
WU Hong-ying
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
HE Xin
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
LI De-guan
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
WANG Xiao-chun
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
ZHANG Heng
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China
LU Lu
Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, China